Cargando…
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
BACKGROUND: Recently, the US Food and Drug Administration (FDA) has approved immune checkpoint blockade (ICB) for treating cancer patients with tumor mutation burden (TMB) >10 mutations/megabase (mut/Mb). However, high TMB (TMB-H) defined by >10 mut/Mb fails to predict ICB response across diff...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804687/ https://www.ncbi.nlm.nih.gov/pubmed/35101940 http://dx.doi.org/10.1136/jitc-2021-003087 |